Table 3B Treatment-related adverse events occurring in at least 3 (>10%) patients

From: Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

Adverse event

Number (%) of patients

Fatigue

16 (36.4)

Rash

13 (29.5)

Nausea

12 (27.3)

Pyrexia

8 (18.2)

Infusion-related reaction

8 (18.2)

Chills

7 (15.9)

Decreased appetite

7 (15.9)

Blood creatinine increased

6 (13.6)

Dyspepsia

6 (13.6)

Pruritis

6 (13.6)

AST increased

5 (11.4)

Vomiting

5 (11.4)

Thrombocytopenia

4 (9.1)

Renal injury

3 (6.8)

Constipation

3 (6.8)

Hyperkalaemia

3 (6.8)

Hypotension

3 (6.8)

Proteinuria

3 (6.8)

  1. Abbreviation: AST=aspartate aminotransferase.
Back to article page